Integrated Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) enables cancer staging and treatment monitoring with high sensitivity, high soft tissue contrast, and added metabolic information1,2,3,4. In adult patients, PET/MRI performed equally well as PET/CT for staging of established cancers5,6,7. In the future, liquid biopsies will likely lead to earlier detection of cancer development (e.g., through transcriptomes and circulating DNA) and require more sensitive imaging tests than are currently available to find small tumors in the body8. This might put PET/MRI into a superior position to evaluate the whole body and detect cancers in anatomical areas that have been classically evaluated with MRI alone, such as the brain, neck, abdomen/pelvis, and musculoskeletal system.
For pediatric patients, PET/MRI has several advantages over PET/CT: First, PET/MRI provides a markedly reduced radiation exposure of the patient by up to 74%4. This can be achieved by using ionizing radiation-free MRI instead of CT technologies for anatomical co-registration of PET data. In addition, the increased sensitivity of modern PET detector systems9 and longer PET data acquisition during an MRI scan enables significant reduction of administered radiotracer doses by 30-50% compared to current PET/CT protocols4. Second, the possibility of combining staging scans of the primary tumor and the whole body saves time and avoids duplicate sedations for some patients, such as patients with bone and soft tissue sarcomas. However, a "one stop" staging scan is only clinically feasible if all PET/MRI data (local tumor and whole body) can be acquired in an efficient manner and if the abundance of resultant image data is presented in an easily digestible format to the radiologist. The protocol presented here will provide step-by-step instructions for the acquisition of PET/MRI data that can be used for clinical staging of children with cancer, with particular attention to specific needs of the pediatric population.